Company performance
Add to research
Current Price
as of Feb 07, 2025$0.45
P/E Ratio
N/A
Market Cap
$26.04M
Description
Add to research
BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.
Metrics
Add to research
Overview
- HQSan Diego, CA
- SectorHealth Technology
- IndustryBiotechnology
- TickerBCAB
- Price$0.4488-10.24%
Trading Information
- Market cap$26.04M
- Float83.93%
- Average Daily Volume (1m)688,360
- Average Daily Volume (3m)1,101,158
- EPS-$1.70
Company
- Revenue$11.00M
- Rev growth (1yr)N/A
- Net income-$10.59M
- Gross margin97.93%
- EBITDA margin-100.38%
- EBITDA-$11.04M
- EV$29.81M
- EV/Revenue2.71
- P/EN/A
- P/S1.97
- P/B0.94
- Debt/Equity5.45
Documents
Add to research
SEC Filings
Factset Street Account
Earnings Calls
Factset